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Abstract 
It has been generally accepted for over 
twenty years that epinephrine stimulates platelet 
aggregation without inducing shape change. 
However, it has been recently reported that 
discoid platelets are not recruited into ADP-or 
epinephrine-stimulated aggregates. Previous work 
in our laboratory has suggested that platelet 
shape change is necessary for the binding of 
fibrinogen to its surface receptor, which is a 
prerequisite for platelet aggregation. These 
studies seem to indicate that epinephrine-induced 
platelet aggregation does involve shape change. 
To investigate this possibility, the extent of 
shape change and fibrinogen binding in 
suspensions of epinephrine- and ADP-activated and 
control platelets was assessed by scanning 
electron microscopy (SEM). Platelets were 
incubated with 20 µM epinephrine, 20 µM ADP, or 
vehicle and labelled with 18 nm gold beads 
conjugated to fibrinogen or to a monoclonal 
antibody directed against the glycoprotein 
!lb/Illa complex which comprises the fibrinogen 
receptor. Results indicate that shape change 
does occur in epinephrine-activated platelets as 
well as ADP-activated platelets. Although GP 
!lb/Illa was shown to be present on both discoid 
and shape-changed, pseudopodial platelets, a 
significant degree of fibrinogen binding did not 
occur earlier than the pseudopodial stage in 
either activated or control suspensions. 
Platelet aggregation studies showed that the 
majority of platelets involved in aggregates had 
changed shape in both ADP-and epinephrine-
treated platelet suspensions. These studies 
suggest that epinephrine- and ADP-induced 
platelet aggregation occurs via the exposure of 
fibrinogen receptors on shape-changed platelets. 
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Introduction 
Platelet membrane glycoproteins regulate the 
hemostatic activities of platelets, especially 
those of adherence and aggregation. The 
fibrinogen receptor is of particular interest in 
platelet studies because soluble fibrinogen has 
been shown to be essential for platelet aggregation 
(13,20,35,36,38,44,50,51), and platelets 
deficient in the glycoproteins which comprise the 
fibrinogen receptor do not bind fibrinogen and do 
not aggregate (6,11,34,45). 
Following exposure to foreign surfaces or to 
various activating agents, such as ADP or 
thrombin, platelets undergo a well-characterized 
activation sequence involving extensive shape 
change, which is correlated with cytoskeletal 
reorganization involving the polymerization of 
actin into microfilaments 
(2,4,5,8,19,26,53,56). We have examined relative 
numbers and distribution of the fibrinogen 
receptor on individual human platelets by 
labelling the receptor with colloidal gold-
conjugated ligand or gold-conjugated antibodies, 
followed by observation using scanning electron 
microscopy (SEM). Thus, we have been able to 
study, in individual platelets, how relative 
receptor numbers and receptor distribution relate 
to cell activation state. By means of 
correlative high voltage transmission electron 
microscopy (HVEM) of whole mounts, we have 
observed the relationship of surface receptors to 
the underlying cytoskeleton (4,23,24,33). 
The glycoprotein llb/llla complex (GP 
llb/llla) has been shown to serve as the platelet 
receptor for fibrinogen, and also apparently for 
other plasma proteins, such as fibronectin, which 
contain the RGD (arg-gly-asp) amino acid sequence 
(48). Our previous studies of the GP !lb/Illa 
fibrinogen receptor have been carried out on 
surface-activated platelets, and have shown that 
the fibrinogen-gold labels (FGN/Au) will not bind 
to platelets until significant shape change has 
occurred (4,23,24,33). This correlates well with 
findings of classical radiolabelled ligand 
binding studies, which indicate that fibrinogen 
does not bind to an unactivated population of 
platelets (6,27,28,44,47). However, the 
fibrinogen receptor is present on the surface of 
even unactivated platelets, as is demonstrated by 
the binding of a monoclonal antibody (3) which is 
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directed against the GP !lb/Illa complex and has 
been shown to inhibit fibrinogen binding (12), 
and also by the binding of small fragments of the 
gamma chain of fibrinogen (21). In addition, it 
has been demonstrated that the advantage ligands 
with small Stokes radii have in gaining access to 
GP !lb/Illa over larger ligands is decreased upon 
activation (10). 
The results of these previous studies 
suggest that the shape change component of 
platelet activation may be a prerequisite for 
fibrinogen binding by acting to remove steric 
hindrance caused by other platelet membrane 
glycoproteins (33). Fibrinogen binding may also 
be closely associated with cytoskeletal changes 
coincident with shape change, which may direct a 
reorientation of the receptor in the plane of the 
membrane. Since soluble fibrinogen is required 
for platelet aggregation, it follows that shape 
change may also be a prerequisite for platelet 
aggregation due to a fibrinogen binding 
requirement. 
Arguments against the proposed relationship 
between platelet shape change, fibrinogen 
binding, and aggregation stem from results which 
suggest that although platelets stimulated by 
most aggregating agents, such as ADP or thrombin, 
change shape prior to aggregation, platelets 
appear to aggregate in response to epinephrine 
without concurrent shape change (7,29,40,42). 
However, Milton and Frojmovic have recently 
examined the shapes of platelets in ADP-and 
epinephrine-aggregated stirred suspensions by the 
use of phase contrast microscopy (30). They 
observed a transient increase, followed by 
disappearance, of free discoid platelets 
throughout the course of aggregation, and an 
accompanying increase in numbers of free 
pseudopodial platelets. They concluded that 
shape-changed platelets were preferentially 
recruited into early aggregates, whether the 
aggregation was induced by ADP or epinephrine. 
We presently report the use of SEM to 
examine the shapes of individual platelets 
activated by epinephrine and ADP to address the 
question of epinephrine- and ADP-induced platelet 
shape change. In addition, we have used 
colloidal gold labelling to examine binding to 
the fibrinogen receptor in epinephrine- and ADP-
activated suspensions. 
Materials and Methods 
Preparation of Colloidal Gold 
A stock solution of colloidal gold granules 
having an average diameter of 18-20 nm was 
prepared by reducing HAuCl4with trisodium citrate 
(14-18). A 4% solution of HAuCl4 (0.5 ml) was 
added to 200 ml of deionized distilled water and 
brought to a boil. Freshly prepared 1% trisodium 
citrate (5.0 ml} was added rapidly to the boiling 
mixture and refluxed for 30 min. A color change 
from dark blue to red, indicative of the 
formation of monodisperse colloidal particles, 
occurs during heating. The resulting colloidal 
gold solution was stored at 4°C under sterile 
conditions. Prior to conjugation with protein, 
the pH of the solution was adjusted for 
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optimal protein adsorption with 0.2 N K2co, as 
measured by gel-filled combination elecEro~e (No. 
9115, Orion Research, Inc., Cambridge,MA). 
Previous studies have shown the optimal pH to be 
at or slightly above the pl of the protein 
(3,16). 
Conjugation of Protein to Colloidal Gold 
The minimum concentration of protein 
necessary to stabilize the colloidal gold was 
determined by adsorption isotherms (15,18). A 
series of protein solutions of increasing 
concentration were made up to 1.0 ml in deionized 
distilled water and added to 5.0 ml of the gold 
solution at optimal pH. After 1 min. at room 
temperature, 1.0 ml of 10% NaCl was added to the 
protein-gold. Inadequate stabilization of the 
colloid results in flocculation of the gold 
granules, indicated by a color change from red to 
blue. 
Protein in 10-50% excess of the amount 
required to stabilize 10 m1 of the gold granules 
was brought to 1.0 ml with sterile filtered (0.22 
µm Millipore, Type GS, Millipore Corporation, 
Bedford, MA) deionized distilled water. Sterile 
filtered (0.22 µm Millipore) colloidal gold was 
then added to bring the volume to 10.0 ml and 
mixed gently. After 5 min. at room temperature, 
0.5 ml of freshly prepared and prefiltered (0.45 
µm Millipore, Type HA) polyethylene glycol (MW 
20,000, Sigma Chemical Co., St. Louis, MO) was 
added to further coat and stabilize the 
granules. The protein-gold was concentrated and 
separated from excess protein by centrifugation 
in polycarbonate tubes at 8700 x g for 30 min. 
The supernatant was discarded, and the 
concentrated red pool resuspended to 1.0 ml in 
sterile filtered (0.22 µm Millipore) protein-free 
Tyrode's buffer, pH 7.3. 
Protein Preparation 
Human fibrinogen (Sigma) was dissolved in 
Tris-buffered saline (TBS, 0.01 M Tris, 0.15 M 
NaCl}, pH 7.4. Contaminating fibronectin was 
removed by passing the sample over an affinity 
column of gelatin-agarose (32). Aliquots of 
relatively fibronectin-free (s 0.5% protein by 
weight as determined by fibronectin ELISA and 
SOS-PAGE) fibrinogen of -1.0 mg/ml were frozen in 
dry ice-isopropanol and stored at -70°C. Gels 
showed that other protein contaminants (e.g., 
plasmin[ogen]) were not present in appreciable 
amounts. Prior to use, samples were dialyzed 
overnight against 0.005 M NaCl and centrifuged at 
15,000 x g for 20 min. to remove aggregates. 
The monoclonal antibody 10E5, which is 
directed against the human platelet glycoprotein 
llb/llla complex (GP !lb/Illa) (12), was a gift 
of Dr. Barry Coller (State University of New York 
at Stony Brook}. Samples of -1.0 mg/ml were 
stored at 4°C. 
Stock solutions of normal human lgG (Hu IgG, 
5 mg/ml) and bovine serum albumin (BSA, 2-5 
mg/ml) were prepared in deionized distilled water 
and diluted to the desired concentration. Both 
proteins were purchased (Sigma) as lyophilized 
powders, and were stored at 0°C after 
reconstitution. 
Labelling Fibrinogen Receptors in Platelet Suspensions 
Platelet Preparation 
Platelets were obtained from normal healthy 
adult volunteers by antecubital venipuncture. 
Blood samples were anticoagulated with either 10 
mM EGTA or 0.38% trisodium citrate. Platelet-
rich plasma (PRP) was prepared by centrifugation 
of whole blood at 140 x g for 15 min. at room 
temperature. For aggregation studies, PRP was 
prepared by centrifuging citrated blood at 100 x 
g for 10 min. in order to obtain a platelet count 
high enough to allow the instrument to detect 
platelet aggregation. Platelets were separated 
from plasma proteins by gel-filtration on a 
column of Sepharose CL-2B. The column was 
equilibrated with calcium-free Tyrode's buffer, 
pH 7.3 (136 mM NaCl, 2.7 mM KCl, 0.42 mM NaH2P04, 
12 mM NaHC03, 2 mM MgCl2, 5 mM dextrose, and 2 
g/l BSA). Gel-filtered platelets (GFP) were 
collected in the void volume and were activated 
either in suspension or on Formvar-coated nickel 
Maxtaform grids (E.F. Fullman, Schenectady, NY). 
Labelling the Fibrinogen Receptor 
Drops of GFP were allowed to surface 
activate on Formvar-coated grids in a moist 
chamber maintained at 37°C for -20 min. Filmed 
grids containing adherent platelets were rinsed 
in protein-free buffer after a majority of the 
platelets were judged to be well-spread, as 
observed by phase contrast microscopy. Surface-
activated platelets were labelled by incubating 
individual grids in 20 µl drops of the 
appropriate gold conjugate (FGN/Au, 10E5/Au, Hu 
IgG/Au, or BSA/Au) for 5 min. at room 
temperature. The grids were then thoroughly 
washed in protein-free buffer and prepared for 
electron microscopy. 
GFP were activated in suspension by 
incubation with 20 µM epinephrine bitartrate or 
20 µM adenosine diphosphate (both from Sigma) for 
5 min. at 37°C. Aliquots (100 µl) of the 
activated platelet suspension were then incubated 
with an equal volume of label, consisting of 50 
µl gold-conjugated protein and 50 µl protein-free 
buffer supplemented with CaCl2 to give a final 
Ca+ con~intration (in suspension of activated 
GFP + Ca -supplemented label) of 1 mM. 
Activation/labelling was stopped by addition of 
10 ml of 1% glutaraldehyde in 0.1 M HEPES, pH 
7.3. After a 30 min. fixation, platelets were 
collected by filtration on 0.4 µm pore size 
polycarbonate membranes (13 mm diameter 
Nuclepore, Nuclepore Corporation, Pleasanton, CA) 
and prepared for SEM. 
Figure 1. Surface-activated platelets labelled 
with 18 nm colloidal gold conjugated to human 
fibrinogen (FGN/Au). Early in the spreading 
process (A), very few FGN/Au labels bind 
(arrows). As activation continues and the 
hyaloplasm of the platelets flattens (B), more 
labels bind over the entire platelet surface, 
including on the pseudopodia (arrows). As 
spreading continues, the FGN/Au labels begin to 
clear from the outer edges of the platelet 
surface (C) until they are completely centralized 
in the plane of the membrane, as in this nearly 
fully-spread form (D). Bar = 1 µm. 
74 7 
J.A. Oliver and R.M. Albrecht 
Aggregation Studies 
Aggregation was monitored in a Payton dual 
channel aggregometer (Payton Scientific Inc., 
Buffalo, NY). GFP at ~152i000/µl were 
supplemented with 1 mM Ca (final concentration) 
and 200 µg/ml human FGN, resulting in a final 
platelet count of ~120,000/µl. The suspensions 
of GFP (500 µl) were maintained at 37°C and 
stirred at 1000 rpm with teflon-coated magnetic 
stir bars in siliconized cuvettes. Activating 
agents were added in small volumes (1/100 volume 
of GFP), and responses recorded on a dual channel 
Payton Aggrecorder. Aggregation was stopped by 
the addition of 10 ml of 1% glutaraldehyde in 0.1 
M HEPES, pH 7.3. Samples were fixed for 30 min. 
at room temperature, collected on filters, and 
prepared for SEM. 
Scanning Electron Microscopy 
All samples were fixed in 0.1 M HEPES-
buffered 1% glutaraldehyde, pH 7.3, for 30 min. 
at room temperature, and post-fixed in 0.05% 
HEPES-buffered Oso4 for 15 min. Specimens were 
dehydrated through a graded series of ethanol to 
absolute ethanol, itself dried by storage over 
molecular sieve. Samples were dried by the 
critical point procedure in an apparatus equipped 
with an in-line molecular sieve and a hydrophobic 
water-excluding filter. Samples were sputter 
coated with ~10 nm gold-palladium (Auto 
Conductavac, SeeVac, Inc., Pittsburgh, PA) and 
viewed on a JEOL JSM-35C scanning electron 
microscope at 15 kV accelerating voltage. 
Results 
The binding pattern of FGN/Au to surface-
activated human platelets is shown in Figures 1 
A~D. Little or no labelling occurs on platelets 
in relatively early stages of activation. 
However, flattened pseudopodial platelets show 
extensive binding of FGN/Au over the entire 
surface, including out onto the pseudopodia. We 
have previously shown that as platelet activation 
and spreading continue, the FGN/Au clears from 
the outer edges. Finally, in fully spread 
platelets, FGN/Au labels are centralized in the 
plane of the membrane. Correlative HVEM analysis 
demonstrates that the individual FGN/Au labels 
are localized exclusively over the inner 
filamentous zone of the subjacent cytoskeleton 
(23). 
In contrast to the extensive labelling 
observed on highly shape-changed, surface-
activated platelets, platelets labelled in 
suspension show minimal binding of FGN/Au. 
Figure 2A shows the labelling of unactivated 
platelets incubated in suspension with FGN/Au. 
The majority of platelets in these samples appear 
to remain round or discoid, or display one short 
spicule. However, some platelets exhibit 
pseudopodia, even in the absence of a stimulating 
agent or surface. The FGN/Au labelling observed 
in unactivated suspensions appears to occur on 
these shape-changed, pseudopodial platelets 
rather than on those which are round or discoid, 
or which have one spicule. 
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A seemingly greater proportion of shape-
changed platelets was observed in activated 
suspensions (not shown) than was observed in 
unactivated samples. Similarly-shaped platelets 
from either ADP-or epinephrine-treated samples 
demonstrate similar degrees of FGN/Au binding 
(Figures 28 and 2C). Relatively unchanged 
platelets do not exhibit appreciable FGN/Au 
labelling, as was the case with unactivated 
suspensions. Binding of FGN/Au occurs primarily 
on platelets with two or more pseudopodia, 
whether the activating agent is 20 µM ADP or 20 
µM epinephrine. The FGN/Au labelling observed in 
all suspensions was also markedly less than that 
observed on the more extensively shape-changed 
surface-activated platelets (compare Figures 2 A-
C with Figures lC and 10). 
To test for the presence of the GP !Ib/l!Ia 
fibrinogen receptor, the binding of gold-
conjugated anti-GP Ilb/llla (10E5/Au) was 
examined. In unactivated platelet suspensions 
(Figure 3A), both round and pseudopodial 
platelets demonstrate considerable binding of 
10E5/Au. The labelling occurs over the entire 
surface of the platelets, including the 
pseudopodia. Similarly, both round and 
pseudopodial platelets in suspensions activated 
with 20 µM epinephrine bound 10E5/Au overt e 
entire platelet surface (Figure 38). No 
difference in 10E5/Au labelling was noted between 
control and epinephrine-activated suspensions. 
Neither surface-activated platelets nor platelet 
suspensions (unactivated, epinephrine-activated, 
or ADP-activated) incubated with Hu IgG/Au or 
BSA/Au demonstrated labelling. 
The relationship of platelet shape change to 
aggregation stimulated by ADP or epinephrine was 
also examined. Suspen2ions of GFP supplemented with fibrinogen and Ca+ were activated with 20 
µM ADP or 20 µM epinephrine, and the course of 
aggregation was followed. HEPES-buffered 
glutaraldehyde was added after maximal 
aggregation was achieved, and the samples were 
processed for SEM. The resultant aggregation 
curves are shown in Figure 4. ADP produced more 
rapid and more extensive aggregation than 
epinephrine, as has been previously reported 
(39,47,50). 
The shape change of both aggregated and non-
aggregated platelets from these samples is shown 
in Figures 5 and 6. After treatment with 20 µM 
ADP, all the platelets found in aggregates 
possess multiple pseudopodia. In addition, a 
large number of non-aggregated platelets are 
shape-changed; however, any round or disco'd 
platelets in the sample are found among the non-
aggregated population rather than involved in 
aggregates. Similarly, after treatment with 20 
µM epinephrine, all the aggregated platelets 
display multiple pseudopodia, and round or 
discoid platelets are found exclusively in :he 
non-aggregated portion of the sample. 
Discussion 
The degree of labelling we have observed on 
round or discoid, and also on shape-changed, 
platelets with 10E5/Au indicates that the Gl 
lib/Illa fibrinogen receptor is present on :he 
Labelling Fibrinogen Receptors in Platelet Suspensions 
Figure 2. FGN/Au labelling of platelets 
activated in suspension and collected on 
polycarbonate filter membranes. Even in 
unstimulated suspensions (A), a few platelets 
possess pseudopodia and bind FGN/Au (arrows), 
whereas only an occasional label can be observed 
on round and discoid platelets. Following 
stimulation with 20 µM ADP (B) or 20 µM 
epinephrine (C), a higher proportion of platelets 
are shape-changed (not shown), but binding of 
FGN/Au (arrows) is still primarily limited to 
pseudopodial platelets regardless of stimulating 
agent. The holes in the background are pores of 
the filter membrane. Bar = 1 µm. 
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Figure 3. Platelets labelled in suspension with 
18 nm colloidal gold conjugated to an antibody 
directed against the GP !lb/Illa complex 
(10E5/Au). As also shown in Figure 2A, 
unactivated suspensions contain a few 
pseudopodial platelets (3A). However, in 
contrast to the labelling observed with FGN/Au, 
10E5/Au (arrows) binds to both unactivated round 
or discoid platelets (seen at the top right of 
the field), and pseudopodial platelets. 
Following activation with 20 µM epinephrine (3B), 
the labelling pattern of 10E5/Au remains the 
same; i.e., both unchanged and pseudopodial 
platelets express the GP !lb/Illa fibrinogen 
receptor. Bar = 1 µm. 
surface regardless of platelet shape. Treatment 
of platelet suspensions with epinephrine prior to 
labelling does not alter the binding of 10E5/Au 
to individual platelets as compared to that 
observed in untreated samples. Thus, epinephrine 
activation does not cause an increase in the 
expression of the ·GP !lb/Illa fibrinogen receptor 
on the platelet surface. 
Binding of FGN/Au to unactivated or early 
activation stage platelets in suspension is 
sparse as compared to the FGN/Au labelling seen 
on highly shape-changed, late activation stage 
surface-activated platelets. The binding which 
J.A. Oliver and R.M. Albrecht 
Figure 4. Aggregometer tracings of susp~nsions 
of gel-filtered platelets su~plemented with 200 
µg/ml fibrinogen and 1 mM Ca T• then activated 
with 20 µM ADP (A) and 20 µM epinephrine (B). 
Time increases along the abscissa, while the 
ordinate scale indicates increases in light 
transmission. Maximum deflection was set with 
the Tyrode's buffer in which the platelets were 
suspended. Activating agents were added at the 
arrows. Upward deflection of the curve at the 
end of the plateau is due to the volume change 
upon the addition of HEPES-buffered 
glutaraldehyde to the cuvette. 
does occur appears to be limited to those 
platelets in which the development of pseudopodia 
and an accompanying increase in surface area have 
taken place. This is the case whether the 
platelets are from an untreated population, or 
whether they are activated with ADP or 
epinephrine. In contrast, 10E5/Au labels 
unactivated and early activation stage platelets 
in suspension very well; the density of 10E5/Au 
labelling appears to be quite similar to that of 
FGN/Au on late and final stage surface-activated 
platelets. Apparently, the fibrinogen receptor 
is present at all stages of platelet activation, 
but not available to FGN/Au until a certain 
degree of activation has occurred. 
SEM analysis of platelet suspensions fixed 
at the point of maximum aggregation in response 
to ADP (Figures 4A and 5) and epinephrine 
(Figures 4B and 6) clearly demonstrates that only 
shape-changed, pseudopodial platelets participate 
in aggregation. A high proportion of the non-
aggregated platelets have also developed 
pseudopodia in both the ADP-and epinephrine-
activated suspensions. However, any unchanged 
round or discoid platelets in the samples are 
found only among the non-aggregated population. 
Our present study has demonstrated that the 
shape of platelets which are able to participate 
in aggregation parallels that of platelets which 
are able to bind FGN/Au. One can infer that the 
binding of fibrinogen and aggregation are related 
and are both preceded by shape change, regardless 
of stimulus. Previous results from our 
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laboratory have demonstrated that FGN/Au binds to 
spreading, dendritic-shaped surface-activated 
platelets, then redistributes in the plane o'. the 
membrane as activation and shape change continue 
to their final stages (4,23,24). The "Rainforest 
Hypothesis" (33) proposes that shape change must 
precede fibrinogen binding to platelets because 
the increase in membrane surface area during 
spreading reduces "shading" or blocking of 
glycoprotein receptors in the "unde~story" _by 
glycoproteins in the "canopy. 11 By inc~easing the 
distance between individual glycoprotein 
receptors, the II canopy" is in essence eliminated, 
and the GP IIb/IIIa complex which was "shaded" or 
blocked in unactivated platelets, becomes 
accessible to the large fibrinogen molecule. 
Molecules which are smaller and/or more flexible 
than fibrinogen (antibodies directed against the 
GP IIb/IIIa complex, fragments of the gamma chain 
of fibrinogen) are able to bind to unactivated 
platelets by going between glycoproteins of the 
"canopy, 0 and ther~fore do not require in~reased 
surface area to gain access to receptors in the 
"understory." In addition to the increase in 
surface area during shape change, the 
polymerization of actin into microfilaments which 
follows platelet activation supports the 
development of pseudopodia around microfilament 
bundles (9,19,26,37,55,57,58). The conversion of 
actin from the globular to filamentous form has 
also been shown to result in the "tethering" of 
GP IIb/IIIa to the cytoskeleton (25,41,46,49), 
which may produce conformational changes in the 
receptor complex necessary for fibrinogen binding 
to occur. 
In contrast to the current results, several 
previous studies have suggested that epinephrine 
can stimulate platelet aggregation, apparently 
mediated by fibrinogen binding, without producing 
shape change and a concomitant increase in 
surface area or cytoskeletal reorganization. 
These data have been taken as evidence against a 
shape change requirement for platelet aggregation 
or fibrinogen binding. O'Brien (40) followed 
platelet shape change during aggregation by 
assessing the amplitude of oscillations produced 
by a population of stirred platelets in a light 
path. This did not provide extensive information 
on the shape of individual platelets involved in 
aggregates. In addition, it has been shown that 
such turbidometric measurements are insensitive 
to the formation of pseudopodia (1,22,31) which 
are an important indicator of platelet shape 
change. White (54) examined individual 
epinephrine-aggregated platelets by transmission 
electron microscopy; however, the thin sections 
required for the work may not have reflected the 
overall shape of the platelets. Small 
pseudopodia present in sections above or below 
the plane of the individual sections may not have 
been readily detected, and the extent of 
pseudopod formation may have been 
underestimated. Therefore, although these 
previous studies have suggested that shape change 
(development of pseudopodia) is not a requirement 
for fibrinogen binding and platelet aggregation, 
the issue is not entirely resolved. 
The effects of cytochalasin B (CB) on 
platelet shape, aggregability, and fibrinogen-
binding capacity have additionally been taken as 
Labelling Fibrinogen Receptors in Platelet Suspensions 
Figure 5. Platelets from the ADP-aggregated 
sample illustrated in Figure 4A. Platelets 
involved in aggregates (A) all exhibit 
pseudopodia. Although most of the non-aggregated 
platelets (8) also demonstrate shape change, any 
round or discoid platelets (arrow) found in the 
sample are found in the non-aggregated portion 
rather than participating in aggregates. Bar = 
1 µm. 
evidence that shape change is not required for 
aggregation or fibrinogen binding. It has been 
reported that CB-treated platelets seemingly 
remain discoid when aggregated by either 
epinephrine or ADP (54). A later study also 
suggested that pretreatment with CB allowed 
discoid platelets to aggregate in response to 
ADP; in addition, the amount of fibrinogen bound 
to CB-treated, ADP-stimulated platelets was not 
significantly different than the amount bound to 
platelets incubated with the CB vehicle (ethanol) 
rather than CB (43). The reasons for the 
increased aggregability of the non-shape-changed 
platelets is not clear. It is possible that CB 
may have directly or indirectly influenced the 
orientation or distribution of GP !Ib/llla in the 
platelet membrane. However, it should be noted 
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Figure 6. Platelets from the epinephrine-
aggregated sample illustrated in Figure 48. As 
observed in the ADP-activated samples, platelets 
involved in aggregates following epinephrine 
stimulation (A) are also exclusively those which 
are pseudopodial. A somewhat smaller proportion 
of the non-aggregated platelets in the sample 
demonstrate shape change. However, as with the 
ADP-treated sample, round and discoid platelets 
(arrows) are found only among the non-aggregated 
population rather than participating in 
aggregates. Bar= 1 µm. 
that, as in the case of the epinephrine studies, 
platelet shape was evaluated by the techniques of 
thin sectioning and turbidometric assessment of 
the swirling pattern of the platelet suspension, 
respectively. As discussed above, these methods 
may not be particularly sensitive to pseudopod 
formation. Therefore, both the aggregation and 
fibrinogen binding observed in these studies 
could have been due to undetected shape-changed 
platelets. Additional work is necessary to 
clarify this possibility. 
In support of the idea of a shape change 
(development of pseudopodia) requirement for 
platelet aggregation, Milton and Frojmovic (30) 
have reported that shape-changed platelets are 
preferentially recruited into aggregates 
J.A. Oliver and R.M. Albrecht 
following stimulation with either ADP or 
epinephrine. Their conclusions regarding the 
shape of aggregated platelets were based 
primarily on evidence derived from assessing the 
shape of non-aggregated platelets at various 
times throughout aggregation. Their use of light 
microscopy (including phase contrast, darkfield, 
and differential-interference contrast) did not 
permit detailed observation of individual 
platelets in aggregates. Therefore, in the 
current study, we have employed SEM analysis of 
platelet shape change in response to ADP and 
epinephrine stimulation to provide additional 
evidence concerning the shape of activated and 
aggregated platelets, and also to explore the 
role of fibrinogen binding in platelet 
aggregation. 
Although an ADP scavenger such as apyrase 
was not used in the epinephrine-activated samples 
shown here, we believe the shape change 
illustrated is an effect of epinephrine and is 
not due to ADP secreted from dense granules. In 
preliminary studies, we have observed that 
stirred suspensions which are fixed at very early 
time points (30 sec. or less) following exposure 
to epinephrine contain small (4-5 platelets) 
aggregates of pseudopodial platelets (not 
shown). The effects of ADP in epinephrine-
treated suspensions are thought to be more 
apparent on the much larger aggregates associated 
with the second wave of aggregation (52). SEM 
analysis of epinephrine-aggregated GFP in the 
presence of an ADP scavenger and/or utilization 
of lumiaggregometry (simultaneous measurement of 
aggregation and secretion by means of the 
luciferin-luciferase system) in conjunction with 
SEM will be required in order to address this 
important issue. In addition, localization of 
fibrinogen on aggregated platelets, as well as 
investigation of the temporal relationship 
between fibrinogen binding and platelet 
aggregation, is warranted in order to more 
clearly elucidate the mechanism(s) underlying 
platelet-platelet interactions. 
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Discussion with Reviewers 
M.B. Zucker: The general view is that 
circulating platelets are discoidal; perhaps a 
few have one or two pseudopods projecting from 
the rim of the disc. On activation, the 
platelets assume a more spherical configuration 
(though they do not have a smooth surface) and 
they develop more pseudopods. The platelets 
described here as "round" are almost certainly 
discs that have settled onto the surface. Do you 
feel that SEM is a good technique for 
illustrating the thickening of the discs that 
constitutes part of the shape change? Also, 
aggregates formed by epinephrine in warmed, 
aspirin-treated platelet-rich plasma consist 
largely of discs when viewed by phase contrast 
microscopy. As you point out in the Discussion, 
the platelets used in this experiment have 
doubtless been exposed to platelet-derived ADP. 
Do you feel they are suitable for studying the 
shape change caused by epinephrine? 
Authors: We feel that our technique of 
studying epinephrine-induced shape change through 
the use of SEM is superior to the use of phase 
contrast microscopy. The "halo" surrounding the 
cell or platelet in question which occurs in 
phase contrast microscopy obscures the detection 
of small pseudopodia which may be present. This 
is because the modulation transfer function for 
phase contrast microscopy is minimal for objects 
in the size range of small pseudopodia. On the 
other hand, the modulation transfer function is 
nearly half maximal when these objects are viewed 
by differential interference contrast (DIC) 
microscopy. Additionally, video enhancement can 
be applied to boost the range of contrast 
obtainable when viewing objects of this size by 
DIC microscopy. In our own work (unpublished), 
we have found that warmed, aspirin-treated 
platelets which are activated with 20 µM 
epinephrine for 5 minutes and then fixed in 1% 
glutaraldehyde do not appear to possess 
pseudopodia when viewed by phase contrast 
microscopy. However, platelets taken from this 
same sample are observed to possess multiple 
pseudopodia when viewed by video-enhanced DIC 
microscopy. Therefore, we do not feel that phase 
contrast microscopy is the best method for 
assessing the platelet shape change response. 
With regard to the discoid (as opposed to 
spherical) appearance of epinephrine-treated 
platelets, we believe that the important aspect 
of the response is not the thickening of the 
discs, but the development of pseudopodia: This 
can be determined by the use of stereo pairs of 
scanning electon micrographs (Figure 7) which 
provide a three-dimensional view of the sample. 
The platelets in this stereo pair are from the 
same sample as seen in Figure 2C. FGN/Au labels 
are clearly seen to select not for round over 
discoid platelets, but for platelets which have 
developed pseudopodia as opposed to those which 
have not. 
J.F. Mustard: Epinephrine does not 
aggregate platelets in the presence of 
physiological concentrations of calcium when 
traces of other agonists such as ADP are 
Labelling Fibrinogen Receptors in Platelet Suspensions 
Figure 7. Stereo 
pair of platelets 
from the same 
sample as in 
Figure 2C. See 
text for 
description. 
Bar = 1 µm. 
unavailable. In our own work, studies that have 
been carried out in platelets in a low calcium 
medium led to an activation of the arachidonate 
pathway that produces aggregation which is not 
due to the primary stimulus, but due to the 
secondary effect of aggregation on the 
arachidonate pathway. This can be blocked by 
treatment of the cyclo-oxygenase with a non-
steroidal anti-inflammatory drug or by making 
certain that the platelets are suspended in the 
presence of physiological concentrations of 
calcium and that there are no traces of other 
agonists such as ADP in the suspending medium. 
Do you feel that a likely explanation for your 
observed epinephrine effect is that, in a medium 
with low calcium, the epinephrine induced the 
platelets to stick transiently to each other as 
discs, which then led to activation of the 
arachidonate pathway which produced shape change 
in the larger aggregates {Figures 5 and 6)? 
Authors: There are reports in the 
literature of platelets exhibiting a primary 
aggregation response to epinephrine after .. 
treatment with aspirin (J.S. Bennett, G. V1la1re, 
J.W. Burch, J Clin Invest, 68:981-987, 1981) and 
after treatment with aspirin and subsequent 
incubation with either apyrase or creatine 
phosphate/creatine phosphokinase. (E.I. 
Peerschke, Blood, 60:71-77, 1982). Although both 
arachidonate metabolites and secreted ADP may 
have played a role in the shape change observed 
in the large aggregates, we have noted similar 
shape change in the small, initial aggregates 
associated with primary aggregation. Since all 
platelet suspensions were supplemented with a 
physiological concentration of calcium ions, we 
do not feel we have stimulated the arachidonate 
pathway outside of the primary epinephrine 
stimulus. Therefore, we maintain the point that 
the shape of aggregated platelets {Figures 5A and 
6A) parallels that of platelets which are able to 
bind FGN/Au. 
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M.M. Frojmovic: How do you know that an 
accompanying change in surface area has taken 
place with shape change? This is expected (see 
M.M. Frojmovic and J.G. Milton, Physiological 
Reviews, 62:185-261, 1982), especially for ADP-
activatedplatelets, but more quantitative 
studies are generally required in this area. 
Authors: Our claim that an increase in 
surface area accompanies the development of 
pseudopodia is based on two pieces of evidence. 
First, although we have not made direct . 
morphometric measurements, the apparent size of 
the main body of the platelet does not decrease 
when pseudopodia begin to appear, as would be 
expected if the ratio of surface area to internal 
area did not increase. Second, surface area 
comparisons between unactivated and fully spread, 
surface-activated platelets have been calculated 
(see reference 32), and have shown that the 
surface area approximately doubles during the 
surface activation process. It is more likely 
that this two-fold increase occurs throughout 
surface activation as a continuum, much the same 
as the shape change process itself proceeds on a 
continuum, from round or discoid, to 
pseudopodial, spreading pseudopodial, spreading, 
and finally, to the fully spread shapes (see 
Figure 1). We agree, however, that further 
morphometric evaluation of this issue is 
required. 
J.M. Gerrard: It would appear that the 
critical test of the Rainforest Hypothesis 
involves labelling and tagging other 
glycoproteins (e.g., glycoprotein lb) and then . 
looking at the distance between such glycoprote,n 
molecules in the unactivated and activated 
discoid and shape-changed platelets to see if 
indeed there is a relative increased distance 
between these glycoprotein molecules in the areas 
where glycoprotein IIb/IIIa fibrinogen binding 
receptor becomes available. Have you done such 
studies with antibodies that would label 
glycoproteins which might act as a "canopy" or 
covering? 
J.A. Oliver and R.M. Albrecht 
Authors: Actual measurement of the distance 
between labelled glycoprotein molecules would be 
difficult using the system described here because 
of the somewhat limited resolving power of 
traditional SEM. However, the recent 
availability of a low voltage, ultrahigh 
resolution (objects in the 10-20 A range can be 
resolved) SEM would make such experiments 
feasible. It is also possible that binding of 
gold-conjugated native ligands will shed 
additional light on the proposed Rainforest 
Hypothesis. For instance, if glycoprotein Ibis 
a member of the "canopy," incubation with its 
native ligand, van Willebrand factor, may 
partially block subsequent binding of fibrinogen 
to GP IIb/IIIa, which we propose to be a member 
of the understory. On the other hand, incubation 
with fibrinogen should have little effect on the 
subsequent binding of van Willebrand factor if 
the model holds true. 
M.B. Zucker: Your observation that much 
more 10E5/Au than FGN/Au binds to each activated 
platelet is not consistent with the results with 
iodine-labelled material, which indicate about 
the same number of binding sites on activated 
platelets. Do you have any explanation for this? 
Authors: On fully spread, surface-activated 
platelets, we observe nearly equal numbers of 
FGN/Au and 10E5/Au labels. During the activation 
process, labelling with FGN/Au appears to be less 
dense than that seen with 10E5/Au, which labels 
GP IIb/I!Ia very well, even on unactivated 
platelets. We feel that the absence of FGN/Au 
labelling observed on unactivated platelets, and 
the apparently decreased labelling of FGN/Au as 
compared to 10E5/Au on platelets activated in 
suspension, is due to steric hindrance occurring 
at the level of the protein molecule rather than 
at the level of the colloidal gold bead. 
However, the use of a more concentrated colloidal 
suspension of smaller beads for a longer period 
of time may more accurately depict the true 
situation, and permit earlier, more rapid binding 
of FGN/Au to receptors as they become available 
for fibrinogen binding. 
756 
